Protocol Ledger

NCT03562637 · Phase III · ACTIVE NOT RECRUITING

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Interventional Phase III clinical trial protocol NCT03562637 sponsored by OBI Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-05 Enrollment: 575 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03562637
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)575 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03562637
Protocol FieldVerified Registry Value
NCT IdentifierNCT03562637
Consolidated Lead SponsorOBI Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment575 participants (ACTUAL)
Registered Start Date2018-12-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI